Psychedelic effects of psilocybin correlate with serotonin 2A receptor occupancy and plasma psilocin levels
- PMID: 30685771
- PMCID: PMC6785028
- DOI: 10.1038/s41386-019-0324-9
Psychedelic effects of psilocybin correlate with serotonin 2A receptor occupancy and plasma psilocin levels
Erratum in
-
Correction: Psychedelic effects of psilocybin correlate with serotonin 2A receptor occupancy and plasma psilocin levels.Neuropsychopharmacology. 2019 Jun;44(7):1336-1337. doi: 10.1038/s41386-019-0360-5. Neuropsychopharmacology. 2019. PMID: 30846853 Free PMC article.
Abstract
The main psychedelic component of magic mushrooms is psilocybin, which shows promise as a treatment for depression and other mental disorders. Psychedelic effects are believed to emerge through stimulation of serotonin 2A receptors (5-HT2ARs) by psilocybin's active metabolite, psilocin. We here report for the first time the relationship between intensity of psychedelic effects, cerebral 5-HT2AR occupancy and plasma levels of psilocin in humans. Eight healthy volunteers underwent positron emission tomography (PET) scans with the 5-HT2AR agonist radioligand [11C]Cimbi-36: one at baseline and one or two additional scans on the same day after a single oral intake of psilocybin (3-30 mg). 5-HT2AR occupancy was calculated as the percent change in cerebral 5-HT2AR binding relative to baseline. Subjective psychedelic intensity and plasma psilocin levels were measured during the scans. Relations between subjective intensity, 5-HT2AR occupancy, and plasma psilocin levels were modeled using non-linear regression. Psilocybin intake resulted in dose-related 5-HT2AR occupancies up to 72%; plasma psilocin levels and 5-HT2AR occupancy conformed to a single-site binding model. Subjective intensity was correlated with both 5-HT2AR occupancy and psilocin levels as well as questionnaire scores. We report for the first time that intake of psilocybin leads to significant 5-HT2AR occupancy in the human brain, and that both psilocin plasma levels and 5-HT2AR occupancy are closely associated with subjective intensity ratings, strongly supporting that stimulation of 5-HT2AR is a key determinant for the psychedelic experience. Important for clinical studies, psilocin time-concentration curves varied but psilocin levels were closely associated with psychedelic experience.
Conflict of interest statement
The authors declare no competing interests.
Figures




Similar articles
-
A single psilocybin dose is associated with long-term increased mindfulness, preceded by a proportional change in neocortical 5-HT2A receptor binding.Eur Neuropsychopharmacol. 2020 Apr;33:71-80. doi: 10.1016/j.euroneuro.2020.02.001. Epub 2020 Mar 4. Eur Neuropsychopharmacol. 2020. PMID: 32146028
-
Acute psilocybin and ketanserin effects on cerebral blood flow: 5-HT2AR neuromodulation in healthy humans.J Cereb Blood Flow Metab. 2025 Jul;45(7):1385-1401. doi: 10.1177/0271678X251323364. Epub 2025 Feb 26. J Cereb Blood Flow Metab. 2025. PMID: 40007438 Free PMC article. Clinical Trial.
-
Brain serotonin 2A receptor binding predicts subjective temporal and mystical effects of psilocybin in healthy humans.J Psychopharmacol. 2021 Apr;35(4):459-468. doi: 10.1177/0269881120959609. Epub 2020 Oct 8. J Psychopharmacol. 2021. PMID: 33501857
-
The neuropharmacology of sleep paralysis hallucinations: serotonin 2A activation and a novel therapeutic drug.Psychopharmacology (Berl). 2018 Nov;235(11):3083-3091. doi: 10.1007/s00213-018-5042-1. Epub 2018 Oct 5. Psychopharmacology (Berl). 2018. PMID: 30288594 Free PMC article. Review.
-
DARK Classics in Chemical Neuroscience: Psilocybin.ACS Chem Neurosci. 2018 Oct 17;9(10):2438-2447. doi: 10.1021/acschemneuro.8b00186. Epub 2018 Jul 16. ACS Chem Neurosci. 2018. PMID: 29956917 Review.
Cited by
-
Body mass index (BMI) does not predict responses to psilocybin.J Psychopharmacol. 2023 Jan;37(1):107-116. doi: 10.1177/02698811221131994. Epub 2022 Nov 14. J Psychopharmacol. 2023. PMID: 36373934 Free PMC article.
-
Synthetic surprise as the foundation of the psychedelic experience.Neurosci Biobehav Rev. 2024 Feb;157:105538. doi: 10.1016/j.neubiorev.2024.105538. Epub 2024 Jan 12. Neurosci Biobehav Rev. 2024. PMID: 38220035 Free PMC article. Review.
-
Psychedelics and Neural Plasticity: Therapeutic Implications.J Neurosci. 2022 Nov 9;42(45):8439-8449. doi: 10.1523/JNEUROSCI.1121-22.2022. J Neurosci. 2022. PMID: 36351821 Free PMC article.
-
Psilocin suppresses methamphetamine-induced hyperlocomotion and acquisition of conditioned place preference via D2R-mediated ERK signaling.CNS Neurosci Ther. 2023 Mar;29(3):831-841. doi: 10.1111/cns.14054. Epub 2023 Jan 10. CNS Neurosci Ther. 2023. PMID: 36627756 Free PMC article.
-
Editorial: The psychotherapeutic framing of psychedelic drug administration.Front Psychol. 2023 Jan 23;14:1121234. doi: 10.3389/fpsyg.2023.1121234. eCollection 2023. Front Psychol. 2023. PMID: 36760432 Free PMC article. No abstract available.
References
-
- Carhart-Harris RL, Bolstridge M, Rucker J, Day CMJ, Erritzoe D, Kaelen M, et al. Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study. Lancet Psychiatry. 2016;0366:11–13. - PubMed
-
- Griffiths RR, Johnson MW, Carducci MA, Umbricht A, Richards WA, Richards BD, et al. Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: a randomized double-blind trial. J Psychopharmacol. 2016;30:1181–97. doi: 10.1177/0269881116675513. - DOI - PMC - PubMed
-
- Ross S, Bossis A, Guss J, Agin-Liebes G, Malone T, Cohen B, et al. Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial. J Psychopharmacol. 2016;30:1165–80. doi: 10.1177/0269881116675512. - DOI - PMC - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical